Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2014 1
2016 2
2017 2
2018 8
2019 1
2020 8
2021 14
2022 23
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Treatment strategy for insomnia disorder: Japanese expert consensus.
Takaesu Y, Sakurai H, Aoki Y, Takeshima M, Ie K, Matsui K, Utsumi T, Shimura A, Okajima I, Kotorii N, Yamashita H, Suzuki M, Kuriyama K, Shimizu E, Mishima K, Watanabe K, Inada K. Takaesu Y, et al. Among authors: takeshima m. Front Psychiatry. 2023 May 9;14:1168100. doi: 10.3389/fpsyt.2023.1168100. eCollection 2023. Front Psychiatry. 2023. PMID: 37229388 Free PMC article.
Comparison of the efficacy and safety of quetiapine and lithium for bipolar depression: A systematic review and meta-analysis of randomized controlled trials.
Ogasawara M, Takeshima M, Esaki Y, Kaneko Y, Utsumi T, Aoki Y, Watanabe N, Suzuki M, Takaesu Y. Ogasawara M, et al. Among authors: takeshima m. Neuropsychopharmacol Rep. 2022 Dec;42(4):410-420. doi: 10.1002/npr2.12283. Epub 2022 Jul 20. Neuropsychopharmacol Rep. 2022. PMID: 35858678 Free PMC article. Review.
Efficacy and safety of adjunctive therapy to lamotrigine, lithium, or valproate monotherapy in bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
Maruki T, Utsumi T, Takeshima M, Fujiwara Y, Matsui M, Aoki Y, Toda H, Watanabe N, Watanabe K, Takaesu Y. Maruki T, et al. Among authors: takeshima m. Int J Bipolar Disord. 2022 Oct 21;10(1):24. doi: 10.1186/s40345-022-00271-7. Int J Bipolar Disord. 2022. PMID: 36269465 Free PMC article. Review.
Attitudes and Difficulties Associated with Benzodiazepine Discontinuation.
Takeshima M, Aoki Y, Ie K, Katsumoto E, Tsuru E, Tsuboi T, Inada K, Kise M, Watanabe K, Mishima K, Takaesu Y. Takeshima M, et al. Int J Environ Res Public Health. 2022 Nov 30;19(23):15990. doi: 10.3390/ijerph192315990. Int J Environ Res Public Health. 2022. PMID: 36498061 Free PMC article.
Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.
Aoki Y, Takaesu Y, Suzuki M, Okajima I, Takeshima M, Shimura A, Utsumi T, Kotorii N, Yamashita H, Kuriyama K, Watanabe N, Mishima K. Aoki Y, et al. Among authors: takeshima m. Neuropsychopharmacol Rep. 2022 Mar;42(1):10-20. doi: 10.1002/npr2.12219. Epub 2021 Nov 22. Neuropsychopharmacol Rep. 2022. PMID: 34807524 Free PMC article. Review.
Feasibility of a wrist-worn wearable device for estimating mental health status in patients with mental illness.
Nakagome K, Makinodan M, Uratani M, Kato M, Ozaki N, Miyata S, Iwamoto K, Hashimoto N, Toyomaki A, Mishima K, Ogasawara M, Takeshima M, Minato K, Fukami T, Oba M, Takeda K, Oi H. Nakagome K, et al. Among authors: takeshima m. Front Psychiatry. 2023 Jul 20;14:1189765. doi: 10.3389/fpsyt.2023.1189765. eCollection 2023. Front Psychiatry. 2023. PMID: 37547203 Free PMC article.
Management of unspecified anxiety disorder: Expert consensus.
Sakurai H, Inada K, Aoki Y, Takeshima M, Ie K, Kise M, Yoshida E, Tsuboi T, Yamada H, Hori H, Inada Y, Shimizu E, Mishima K, Watanabe K, Takaesu Y. Sakurai H, et al. Among authors: takeshima m. Neuropsychopharmacol Rep. 2023 Jun;43(2):188-194. doi: 10.1002/npr2.12323. Epub 2023 Feb 21. Neuropsychopharmacol Rep. 2023. PMID: 36811273 Free PMC article.
Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study.
Hasegawa N, Yasuda Y, Yasui-Furukori N, Yamada H, Hori H, Ichihashi K, Takaesu Y, Iida H, Muraoka H, Kodaka F, Iga JI, Hashimoto N, Ogasawara K, Ohi K, Fukumoto K, Numata S, Tsuboi T, Usami M, Hishimoto A, Furihata R, Kishimoto T, Nakamura T, Katsumoto E, Ochi S, Nagasawa T, Atake K, Kubota C, Komatsu H, Yamagata H, Ide K, Takeshima M, Kido M, Kikuchi S, Okada T, Matsumoto J, Miura K, Shimazu T, Inada K, Watanabe K, Hashimoto R. Hasegawa N, et al. Among authors: takeshima m. Psychiatry Clin Neurosci. 2023 Oct;77(10):559-568. doi: 10.1111/pcn.13578. Epub 2023 Sep 8. Psychiatry Clin Neurosci. 2023. PMID: 37684711
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
Hashimoto N, Yasui-Furukori N, Hasegawa N, Ishikawa S, Hori H, Iida H, Ichihashi K, Miura K, Matsumoto J, Numata S, Kodaka F, Furihata R, Ohi K, Ogasawara K, Iga JI, Muraoka H, Komatsu H, Takeshima M, Atake K, Kido M, Nakamura T, Kishimoto T, Hishimoto A, Onitsuka T, Okada T, Ochi S, Nagasawa T, Makinodan M, Yamada H, Tsuboi T, Yamada H, Inada K, Watanabe K, Hashimoto R. Hashimoto N, et al. Among authors: takeshima m. BMC Psychiatry. 2023 Jun 28;23(1):473. doi: 10.1186/s12888-023-04908-4. BMC Psychiatry. 2023. PMID: 37380997 Free PMC article.
69 results